Xenon Pharmaceuticals Inc (XENE) Stock Analysis
Verdict: HOLD
Phase 3 XEN1101 data will dictate the $5B valuation — the model sees a momentum-driven run-up supported by a $199M cash fortress.
Investment score: 64/100
Analysis as of
Is Xenon Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
XENE is a high-conviction clinical play with a strong balance sheet but currently sports a rich valuation after a 55% 90-day rally.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 90/100 (weight 10%)
- Risk-Adjusted Return: 65/100 (weight 15%)
Xenon Pharmaceuticals Inc opportunities and risks
What speaks for XENE
- XEN1101 Phase 3 Success
What speaks against XENE
- Binary Clinical Trial Failure
Peers and competitors
- AUPH
- ABUS
- EPRX.TO
- ZYME
- EDT.TO
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| XENE | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.6% |
| AUPH | 7.2x | 7.0x | 13.0x | 89.7% | 100.0% | 8.0% |
| ABUS | 6.2x | 5.4x | 6.2x | 100.0% | 84.0% | -3.4% |
| EPRX.TO | n/a | 0.0x | n/a | 0.0% | 0.0% | -13.0% |
| ZYME | n/a | 23.9x | n/a | 94.4% | -126.3% | -4.0% |
| EDT.TO | n/a | 142.4x | n/a | -79.2% | -1377.2% | -2.8% |
| Peer median | n/a | 7.0x | n/a | 89.7% | 0.0% | -3.4% |
Frequently asked questions about Xenon Pharmaceuticals Inc (XENE)
Is XENE stock a good investment?
The TradeMates model rates Xenon Pharmaceuticals Inc as HOLD with an investment score of 64/100. XENE is a high-conviction clinical play with a strong balance sheet but currently sports a rich valuation after a 55% 90-day rally. This is algorithmic model output, not personal investment advice.
Is XENE stock a buy?
The TradeMates model verdict for XENE is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.